MNPRMonopar Therapeutics Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Rangebound, no clear trend. Price is −8% vs its 200-day average.
A crowded short, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MNPR is trading
Monopar Therapeutics Inc. is −11% over the past year while the S&P 500 is +16%: 27 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −8.5%
vs 200-day average · below trend, but not far
- RSI (14)
- 37
RSI (14) · neutral
- Below its 52-week high
- 43%
Below its 52-week high
Details›
- Last close2026-10-23
- $70.56
- 1 monthS&P 500 −0.94%
- −21%
- 1 yearS&P 500 +16%
- −11%
- 5 yearsS&P 500 +86%
- +187%
- vs 50-day average$95.61
- −26%
- 52-week high
- $124.25
- 52-week low
- $50.12
- Annualised volatility
- 439%
| Year | Return |
|---|---|
| 2026 (year to date) | +8.1% |
| 2025 | +197% |
| 2024 | +1194% |
| 2023 | −86% |
| 2022 | −26% |
| 2021 | −48% |
| 2020 | −63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | +23% |
| Feb | 7 | 2 of 7 | +9.0% |
| Mar | 7 | 1 of 7 | −18% |
| Apr | 7 | 2 of 7 | −3.3% |
| May | 7 | 2 of 7 | −3.8% |
| Jun | 7 | 5 of 7 | +9.9% |
| Jul | 7 | 2 of 7 | −1.7% |
| Aug | 7 | 1 of 7 | −13% |
| Sep | 7 | 2 of 7 | +37% |
| Oct | 7 | 3 of 7 | +18% |
| Nov | 6 | 4 of 6 | +4.7% |
| Dec | 6 | 2 of 6 | −3.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.